Signum Dermalogix Inc.,a private biopharmaceutical company focused on developing new dermatological products and services, entered into a partnership with Elizabeth Arden Inc. focusing on a semi-exclusive global license for the cosmetic functional ingredient Arazine (INCI: N-Acetyl-S-Farnesyl-Cysteine), as well as developing new screening methodologies to measure the antioxidant potential of Arden's other product ingredients.
Arazine, initially discovered at Princeton University, possesses anti-inflammatory and antioxidant properties making it a complement with the Idebenone-ester as key ingredients in Elizabeth Arden's Prevage Anti-aging + Intensive Repair Daily Serum product.
Arazine is the first cosmetic ingredient from Signum Dermalogix's novel technology platform to be commercialized. Maxwell Stock, CEO of Signum Dermalogix, commented, "We are excited about our partnership with Arden, especially given their commitment to bringing a scientific approach to developing new and innovative skin care products. We believe this is just the beginning of a dynamic collaboration that will enable the development of a first in class line of skin care products."
Eduardo Perez, PhD, VP of R&D for Signum Dermalogix, stated, "With Elizabeth Arden's decades of experience in skin care and our R&D and chemical expertise, we look forward to assisting Elizabeth Arden's efforts in producing innovative, high quality skin care products supported with robust scientific data."
Given the successful launch of Arazine in the Prevage line, Signum Dermalogix is now focused on developing a second generation of novel cosmetic ingredients as well as finding a partner to commercialize Arazine in the physician-dispensed channel.